Table 4.
Medical therapy at discharge
| Variable | Index (n = 3372) | Repeat (n = 735) | p value |
|---|---|---|---|
| Anti-arrhythmic drug (AAD) therapy | |||
| Beta-blocker | 74.5% | 70.2% | 0.017 |
| AAD class I | 32.6% (1099/3372) | 30.1% (221/735) | 0.18 |
| AAD class III | 21.4% (722/3372) | 24.4% (179/735) | 0.081 |
| Sotalol | 18.3% (132/722) | 18.4% (33/179) | 0.96 |
| Amiodarone | 79.2% (572/722) | 78.8% (141/179) | 0.89 |
| AAD class III (added after procedure) | 2.6% (19/722) | 2.8% (5/179) | 0.90 |
| AAD class IV | 1.6% (53/3372) | 3.4% (25/735) | < 0.001 |
| Antithrombotic therapy | |||
| ASA | 9.0% (304/3372) | 6.7% (49/735) | 0.040 |
| Clopidogrel | 2.7% (91/3372) | 2.0% (15/735) | 0.31 |
| Vitamin K antagonist | 89.6% (3023/3373) | 91.0% (669/735) | 0.26 |
| Heparin (UFH) | 8.3% (280/3372) | 3.9% (29/735) | < 0.001 |
| Heparin (LMWH) | 63.3% (2136/3372) | 70.3% (517/735) | < 0.001 |
ASA acetylsalicylic acid; UFH unfractionated heparin; LMWH low-molecular-weight heparin; All values given as percentages with total numbers in brackets. P values were calculated by Fisher’s exact test and considered significant if < 0.05.*